Loading organizations...
§ Private Profile · San Diego, CA, USA
Clinical-stage biopharmaceutical company developing targeted protein degraders and molecular glues to treat cancer and inflammatory diseases.
Biotheryx is a clinical-stage biopharmaceutical company developing targeted protein degraders, multi-kinase inhibitors, and molecular glues for cancer and inflammatory diseases, based in San Diego, California. The organization utilizes its proprietary PRODEGY platform to design orally available small molecules that eliminate disease-causing proteins previously considered undruggable by traditional methods. The private biotechnology firm has secured significant capital to advance its clinical pipeline, including a $92 million financing round closed in 2021. Biotheryx is backed by notable institutional investors such as Farallon Capital Management and Cormorant Asset Management, and it established a strategic research collaboration with Incyte in 2023 that includes up to $347 million in potential milestone payments. The enterprise also maintains a scientific advisory board featuring prominent researchers like Kevan M. Shokat. The company was founded in 2007 by former Celgene executives David Stirling and Lawrence Zaslow.
Biotheryx has raised $127.0M across 2 funding rounds.
Biotheryx has raised $127.0M in total across 2 funding rounds.
Biotheryx has raised $127.0M in total across 2 funding rounds.
Biotheryx's investors include Farallon Capital Management, Alexandria Venture Investments, Avidity Partners, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Tekla Capital Management, Wedbush Healthcare Partners.
Biotheryx has raised $127.0M across 2 funding rounds. Most recently, it raised $92.0M Series E in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 20, 2021 | $92M Series E | Farallon Capital Management | Alexandria Venture Investments, Avidity Partners, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Tekla Capital Management, Wedbush Healthcare Partners | Announced |
| Jul 28, 2020 | $35M Series D | Robert Platek | — | Announced |